Doreen Su Yin Tan (Doreen Su-Yin Tan)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Acute Coronary Syndrome

Antiplatelet Therapy

St Segment Elevation Myocardial Infarction

Top Venues

Clinical drug investigation

Cardiovascular drugs and therapy

The pharmacogenomics journal

Journal of human hypertension

This page only lists publications with an associated author ORCID identifier.

Publications

Xin Qin Soh, Doreen Su Yin Tan, Eric Chun Yong Chan
Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Cardiovascular drugs and therapy (2022)
Sarah Wai Yee Tang, Aaron Shengting Mai, Nicholas W S Chew, Wilson Wai Sun Wai Sun Tam, Doreen Su Yin Tan
The clinical impact of anti-hypertensive treatment drug-gene pairs in the asian population: a systematic review of publications in the past decade. Journal of human hypertension (2022)
Ji Heon Kim, Doreen Su Yin Tan, Mark Yan Yee Chan
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore. The pharmacogenomics journal 21 (2) (2021)
Kaavya Narasimhalu, Yoong Kwei Ang, Doreen Su Yin Tan, Deidre Anne De Silva, Kelvin Bryan Tan
Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations. Clinical drug investigation 40 (11) (2020)
Doreen Su Yin Tan, Jernice Wan Xin Aw, Michael Winther, Liuh Ling Goh, Hean Yee Ong, Eric Wee, Jianjun Liu, Han Kiat Ho
CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events. Journal of clinical pharmacy and therapeutics 45 (1) (2019)